Trial Profile
An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BAY 1163877 in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rogaratinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 07 Dec 2017 Status changed from active, no longer recruiting to completed.
- 30 Oct 2017 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
- 21 Jun 2017 Planned End Date changed from 28 Feb 2018 to 30 Nov 2017.